Last update 01 Nov 2024

Supergen Bioenergy Hub

Overview

Related

4
Drugs associated with Supergen Bioenergy Hub
RII-retinamide
Target
RARs
Mechanism
RARs modulators
Active Org.
Chinese Academy of Medical SciencesChinese Academy of Medical Sciences
Originator Org.
Chinese Academy of Medical SciencesChinese Academy of Medical Sciences [+1]
Active Indication
Preleukemia
Inactive Indication
Myelodysplastic Syndromes
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
CN
First Approval Date03 Jun 1999
Ropidoxuridine
Target
thymidine kinase
Mechanism
thymidine kinase inhibitors [+1]
Active Org.
Shuttle Pharmaceuticals Holdings, Inc. [+1]
Originator Org.
Yale UniversityYale University
Active Indication
Glioblastoma, IDH-Wildtype [+1]
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
VEGF121-rGel
Target
VEGF
Mechanism
VEGF inhibitors
Active Org.-
Originator Org.
Avid Bioservices, Inc.Avid Bioservices, Inc.
Active Indication-
Inactive Indication
Neoplasms
Drug Highest PhaseDiscontinued
First Approval Ctry. / Loc.-
First Approval Date-
100 Clinical Results associated with Supergen Bioenergy Hub
Login to view more data
0 Patents (Medical) associated with Supergen Bioenergy Hub
Login to view more data
100 Deals associated with Supergen Bioenergy Hub
Login to view more data
100 Translational Medicine associated with Supergen Bioenergy Hub
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Other
4
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Cancer vaccine(Sarepta Therapeutics, Inc.)
Colorectal Cancer
More
Discontinued
Ropidoxuridine
 ( thymidine kinase )		Astrocytoma
More
Discontinued
VEGF121-rGel
 ( VEGF )		Neoplasms
More
Discontinued
RII-retinamide
 ( RARs )		Myelodysplastic Syndromes
More
Pending
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free